BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Gastric cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
335 results:

  • 1. Plexiform Fibromyxoma in the Stomach: Immunohistochemical Profile and Comprehensive Genetic Characterization.
    Di Mauro A; Rega RA; Leongito M; Albino V; Palaia R; Gualandi A; Belli A; D'Arbitrio I; Moccia P; Tafuto S; De Chiara A; Ottaiano A; Ferrara G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732067
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma.
    Chang HY; Dermawan JK; Kuba MG; Crago AM; Singer S; Tap W; Chi P; D'Angelo S; Rosenbaum E; Antonescu CR
    Genes Chromosomes Cancer; 2024 May; 63(5):e23240. PubMed ID: 38722225
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an vegfr-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
    Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
    Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The pathological roles and potential mechanisms of vascular endothelial growth factor receptor-3 in gastric cancer.
    Li XF; Zhang XJ; Hao FR; Dong XT; Xu GD; Zhang YX
    J Int Med Res; 2024 Mar; 52(3):3000605241234558. PubMed ID: 38518198
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Recent development of vegfr small molecule inhibitors as anticancer agents: A patent review (2021-2023).
    Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
    Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
    Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
    Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Advances in targeted therapy for gastric cancer based on tumor driver genes.
    Wu S; Xu P; Zhang F
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
    Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
    Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.
    Shaopeng Z; Yang Z; Yuan F; Chen H; Zhengjun Q
    Cancer Med; 2024 Jan; 13(2):e6959. PubMed ID: 38349050
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M; Zhang Y; Wang Z; Qian N; Dai G
    Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Rivoceranib, a vegfr-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
    Kang YK; Ryu MH; Di Bartolomeo M; Chau I; Yoon H; Kim JG; Lee KW; Oh SC; Takashima A; Kryzhanivska A; Chao Y; Evesque L; Schenker M; McGinn A; Zhao Y; Lee J; Wyrwicz L; Boku N
    Gastric Cancer; 2024 Mar; 27(2):375-386. PubMed ID: 38281295
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical Management of gastric cancer Treatment Regimens.
    Boilève J; Touchefeu Y; Matysiak-Budnik T
    Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy.
    Wang B; Zhu Y; Wang S; Li Z; Wang L; Rao W; Cheng N; Chen R; Ying J; Xue L
    Gastric Cancer; 2024 Jan; 27(1):86-101. PubMed ID: 38019350
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.
    Hyung S; Ko J; Heo YJ; Blum SM; Kim ST; Park SH; Park JO; Kang WK; Lim HY; Klempner SJ; Lee J
    Sci Adv; 2023 Nov; 9(47):eadk1098. PubMed ID: 38000030
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
    Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
    Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
    Sohel M
    Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genomic and Transcriptomic Characterization of gastric cancer with Bone Metastasis.
    Oh S; Nam SK; Lee KW; Lee HS; Park Y; Kwak Y; Lee KS; Kim JW; Kim JW; Kang M; Park YS; Ahn SH; Suh YS; Park DJ; Kim HH
    Cancer Res Treat; 2024 Jan; 56(1):219-237. PubMed ID: 37591783
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Skip metastasis at the esophageal resection margin in radical gastrectomy: clinical characteristics of 30 cases].
    Liu S; Xia QY; Fu Y; Lu XF; Wang M; Guan WX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jul; 26(7):675-679. PubMed ID: 37583025
    [No Abstract]    [Full Text] [Related]  

  • 19. Solute carrier family 35 member A2 (SLC35A2) is a prognostic biomarker and correlated with immune infiltration in stomach adenocarcinoma.
    Huang Z; Yang H; Lao J; Deng W
    PLoS One; 2023; 18(7):e0287303. PubMed ID: 37467193
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
    Lu G; Wang X; Cheng M; Wang S; Ma K
    Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 17.